The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Baseline covariates impacting overall survival (OS) in a phase III study of men with bone metastases from castration-resistant prostate cancer.
Karim Fizazi
Consultant or Advisory Role - Amgen
Christophe Massard
No relevant relationships to disclose
Matthew Raymond Smith
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Michael E. Rader
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Janet Elizabeth Brown
Consultant or Advisory Role - Amgen
Honoraria - Amgen; Novartis
Research Funding - Amgen; Novartis
Piotr Milecki
Research Funding - Amgen
Neal D. Shore
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Stephane Oudard
Honoraria - Bayer; Novartis; Pfizer; Roche; Sanofi
Lawrence Ivan Karsh
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Michael Anthony Carducci
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Ronaldo DamiĆ£o
No relevant relationships to disclose
Huei Wang
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Carsten Dietrich Goessl
Employment or Leadership Position - Amgen
Stock Ownership - Amgen